Stocks Leading in March. In this article, we are going to take a look at where Mineralys Therapeutics, Inc. (NASDAQ:MLYS) ...

Mineralys Therapeutics (MLYS) announced detailed results from the Phase 2 Advance-HTN trial, one of two pivotal trials evaluating lorundrostat ...

The addition of the aldosterone synthase inhibitor helps patients with resistant hypertension lower their blood pressure.

Among patients with uncontrolled hypertension, the investigational drug lorundrostat brought a significant reduction in blood pressure at 12 weeks compared with placebo, according to a study presented ...

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for conditions related to dysregulated aldosterone, announced it will host a conference ...

Mineralys Therapeutics, Inc. has a 1 year low of $8.24 and a 1 year high of $18.38. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -4.44 and a beta of 1.50.

In this article, we are going to take a look at where Mineralys Therapeutics, Inc. (NASDAQ:MLYS) stands against other stocks that are receiving the most insider investment in March. “The economy ...

RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has announced an upcoming conference call and webinar to highlight ...

Insiders have been showing their love for these four biotech stocks, and one tech stock, lately with huge share purchases.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascentage Pharma Group International Unsponsored ...